Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PDE9A | O76083 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 7/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.39 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838694 | 0.83 | CYP17A1 (0.46) | GSK3BPDE9ARAB9ACYP17A1CYP1A2 | |
| SCHEMBL838153 | 0.81 | RAB9A (0.55) | RAB9ATP53LMNASMN1; SMN2HTT | |
| SCHEMBL839998 | 0.78 | TP53 (0.47) | RAB9ATP53LMNAHTTPIP4K2A | |
| SCHEMBL838986 | 0.76 | RAB9A (0.41) | RAB9ATP53LMNAHTTALDH1A1 | |
| SCHEMBL839756 | 0.76 | XDH (0.46) | RAB9ATP53LMNASLC2A1SLC2A2 | |
| SCHEMBL850157 | 0.76 | TP53 (0.45) | RAB9ATP53LMNAHTTPIP4K2A | |
| SCHEMBL6071371 | 0.74 | GSK3B (0.54) | GSK3BRAB9ACYP17A1CYP1A2TP53 | |
| SCHEMBL838447 | 0.73 | RAB9A (0.40) | GSK3BRAB9ATP53LMNASMN1; SMN2 | |
| SCHEMBL838405 | 0.73 | TP53 (0.44) | RAB9ATP53LMNASMN1; SMN2HTT | |
| SCHEMBL839927 | 0.73 | SLC2A1 (0.44) | RAB9ACYP17A1CYP1A2TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | GSK3B 1784/4885PDE9A 1740/4885RAB9A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.